Table 2.
The sensitivity of DMRTA2 by different types of disease in urine samples
| Discovery seta | Validation seta | Aggregate set | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Type of disease | Samples | DMRTA2-positive | Sensitivity (95%CI) | Samples | DMRTA2-positive | Sensitivity (95%CI) | Samples | DMRTA2-positive | Sensitivity (95%CI) |
| Bladder cancer | 137 | 117 | 85.4% (78.1–90.6%) | 79 | 62 | 78.5% (67.5–86.6%) | 216 | 179 | 82.9% (77.0–87.5%) |
| Carcinomas of renal pelvis | 23 | 18 | 78.3% (55.8–91.7%) | 12 | 11 | 91.7% (59.8–99.6%) | 35 | 29 | 82.9% (65.7–92.8%) |
| Carcinomas of ureter | 13 | 7 | 53.8% (26.1–79.6%) | 6 | 3 | 50.0% (13.9–86.1%) | 19 | 10 | 52.6% (29.5–74.8%) |
| Renal carcinomas | 31 | 0 | 0 | 40 | 2 | 5.0% (0.8–18.2%) | 71 | 2 | 2.8% (0.5–10.7%) |
| Prostate cancers | 13 | 1 | 7.7% (0.4–37.9%) | 49 | 5 | 10.2% (3.8–23.0%) | 62 | 6 | 9.7% (4–20.5%) |
| Benign tumors of bladder | 28 | 3 | 10.7% (2.8–29.4%) | 22 | 7 | 31.8% (14.7–54.9%) | 50 | 10 | 20.0% (10.5–34.1%) |
| Recurring cancers | 22 | 17 | 77.3% (54.2–91.3%) | 8 | 7 | 87.5% (46.7–99.3%) | 30 | 24 | 80.0% (60.8–91.6%) |
| Specificity | Specificity | Specificity | |||||||
| Normalb | 202 | 14 | 93.1%b (88.4–96.0%) | 304 | 24 | 92.1%b (88.3–94.8%) | 506 | 38 | 92.5%b (89.7–94.6%) |
aCutoff CT-value of 37 was used for both discovery and validation set
bNormal controls were not healthy donors but subjects with benign diseases of the urinary tract